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Objective: To determine the prevalence of sexual dysfunction in women diagnosed with early
rheumatoid arthritis (RA) (less than one year of symptoms at the time of diagnosis), as well
as  to evaluate the possible association between sexual dysfunction with AR activity and
functional disability.
Methods: Cross-sectional study assessing women diagnosed with early RA, accompanied
per  protocol in the Brasilia Cohort, Hospital Universitário de Brasília. Demographics, disease
activity index (Disease Activity Score 28 – DAS 28) and functional disability questionnaire
(Health Assessment Questionnaire – HAQ), were obtained by direct interviews. The Female
Sexual Function Index (FSFI) was used questionnaire which contains 19 items that assess
six domains: sexual desire, sexual arousal, vaginal lubrication, orgasm, sexual satisfaction
and pain.
Results: 68 patients studied, of whom 54 (79.4%) reported sexual activity in the last four
weeks. The participants were 49.7 ± 13.7 (mean ± SD) years old and the majority were mar-
ried  (61.4%). The mean DAS 28 was 3.6 ± 1.5 and the mean HAQ was 0.7. The prevalence of
sexual dysfunction (FSFI ≤26) was 79.6%. There was no association of disease activity or
of  functional disability with the occurrence of sexual dysfunction in the female patients
evaluated.
Conclusion: The prevalence of sexual dysfunction found in this study was higher than that
reported in the literature in healthy women. A knowledge of the extent of the problem isneeded to provide adequate therapeutic options for these patients.
©  2014 Elsevier Editora Ltda. All rights reserved.
∗ Corresponding author.
E-mail: thaisferreiracosta@yahoo.com.br (T.F. Costa).
ttp://dx.doi.org/10.1016/j.rbre.2014.10.006
255-5021/© 2014 Elsevier Editora Ltda. All rights reserved.
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Prevalência  de  disfunc¸ão  sexual  entre  pacientes  acompanhadas  na  coorte
Brasília  de  artrite  reumatoide  inicial
Palavras-chave:
Disfunc¸ão sexual
Sexualidade
Artrite reumatoide
Qualidade de vida
r  e  s  u  m  o
Objetivo: Determinar a prevalência de disfunc¸ão sexual em mulheres com diagnóstico de
artrite reumatoide (AR) inicial (menos de um ano de sintomas ao diagnóstico), bem como
avaliar a possível associac¸ão entre disfunc¸ão sexual com atividade da AR e incapacidade
funcional.
Métodos: Estudo transversal, que avaliou mulheres com diagnóstico de AR inicial, acom-
panhadas de forma protocolar na coorte Brasília, no Hospital Universitário de Brasília.
Dados demográﬁcos, índice de atividade da doenc¸a (Disease Activity Score 28 – DAS 28)
e  dados do questionário de incapacidade funcional (Health Assessment Questionnaire –
HAQ) foram obtidos por entrevistas diretas. Usou-se o índice de func¸ão sexual feminina
(Female Sexual Function Index – FSFI), questionário que contém 19 itens que avaliam seis
domínios: desejo sexual, excitac¸ão sexual, lubriﬁcac¸ão vaginal, orgasmo, satisfac¸ão sexual
e  dor.
Resultados: Foram estudadas 68 pacientes, das quais 54 (79,4%) relataram atividade sex-
ual  nas últimas quatro semanas. A média de idade foi de 49,7 ± 13,7 anos e a maioria era
casada (61,4%). O DAS-28 médio foi de 3,6 ± 1,5 e a média do HAQ foi de 0,7. A prevalên-
cia de disfunc¸ão sexual (FSFI ≤26) foi de 79,6%. Não houve associac¸ão de atividade de
doenc¸a  nem de incapacidade funcional com a ocorrência de disfunc¸ão sexual nas pacientes
avaliadas.
Conclusão: A prevalência de disfunc¸ão sexual encontrada neste estudo foi superior
à  relatado na literatura em mulheres saudáveis. Há necessidade de conhecimento
da  extensão do problema para oferecer possibilidades terapêuticas adequadas aos
pacientes.
© 2014 Elsevier Editora Ltda. Todos os direitos reservados.Introduction
Rheumatoid arthritis (RA) is a systemic chronic and progres-
sive disease that preferentially affects the synovial membrane
of joints and can lead to bone and cartilage destruction.1,2
The disease leads to various degrees of disability and has a
profound impact on the social, economic and psychological
aspects of the patient’s life.3
Sexual function (FS) is a major component of quality of
life, with higher amplitude than sexual intercourse itself.4,5
Sexual expression is a crucial part of the individual’s own
identity, and therefore important in all stages of health and
disease.6 A full sexual functioning consists in the transition
between phases, from excitement to relaxation, with plea-
sure and satisfaction.7 Sexual dysfunction (SD) is deﬁned as
the inability to participate in the sexual act with satisfac-
tion, compromising the desire and/or arousal and/or orgasm.4
Sexuality inﬂuences behavior and deﬁnes gender roles; and
both in the physical and psychological sense, becomes part
of the lifestyle of the individual of all ages.3 SD not only
compromises sexual satisfaction, but also overall life satis-
faction, determining a lower quality of life, low self-esteem,
depression, anxiety and prejudice in interpersonal and part-
ner relationship.4 The main risk factors for SD have organic,
psychosocial and sociodemographic origin, with emphasis on
age, family income and education.4,8 Some authors suggestthat female sexual dysfunction sometimes reaches more  than
40% of women.9
Competence, motivation and sexual expression are
decreased in patients with RA.10 Most of the sexual problems
experienced by these patients are related to disease activity,
pain, loss of joint motion, functional disability, or fatigue.11
Other factors include depression, anxiety, loss of self-esteem
and difﬁculty in discussing the disease.11 The percentage of
patients with arthritis who experience sexual problems varies
across studies, from 31 to 76%.4,7,10–12
The two main ﬁelds of sexual problems experienced by
patients with RA are: difﬁculty in performing the sexual act
(sexual disability) and decreased sex drive, reﬂected both in
sexual desire and in a decreased sexual satisfaction. Sexual
incapacity is manifested by problems such as joint pain and
fatigue during intercourse, presented by 50–61% of patients
with RA. Difﬁculty in assuming certain positions when hip
or knee movements are limited and dyspareunia due to vagi-
nal dryness in secondary Sjögren’s syndrome are observed.
Decreased sex drive is manifested by a decreased desire in
50–60% of patients with RA, and by a low frequency of sexual
intercourse in 73% of patients.3,7,13Although SF’s commitment is a major problem for patients
diagnosed with RA, adequate information on this subject are
scarce.3 Sexuality is rarely addressed in questionnaires on
quality of life or during interviews between doctor and patient.
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t is very important that rheumatologists and other health
rofessionals acknowledge the impact that RA promotes
n sexuality, since this knowledge facilitates the discussion
etween doctor and patient, when addressing the inﬂuence
f the disease in several domains of patients’ quality of life.
dditionally, it allows an optimization of the treatment of
A, here encompassing the attention to the patient’s sexual
ifﬁculties.11
No Brazilian data exist on the prevalence of sexual dys-
unction in women with early RA. This study aims to describe
he prevalence of sexual dysfunction in female patients with
arly rheumatoid arthritis followed in the outpatient clinic of
A and to evaluate the possible association between sexual
ysfunction with disease activity and functional disability.
atients  and  methods
A patients pertaining to the Brasília Cohort were evaluated.
rasilia Cohort14–17 is an incident cohort of patients with early
A, accompanied at the outpatient clinic of Rheumatology,
ospital Universitário de Brasília, Universidade de Brasília.
or inclusion in this cohort, early RA is deﬁned as the occur-
ence of compatible joint symptoms (joint pain and swelling
ith an inﬂammatory pattern, with or without morning stiff-
ess or other manifestations suggestive of inﬂammatory joint
isease, assessed by a single observer) lasting more  than 6
eeks and less than 12 months, regardless of the fulﬁllment
f the American College of Rheumatology (ACR) criteria.18
ll patients selected fulﬁlled retrospectively EULAR/ACR 2010
riteria.19
From the time of diagnosis, the patients are followed
rospectively, receiving the standard treatment regimen used
n the Service, including the traditional disease-modifying
ntirheumatic drugs (DMARDs) or biological response mod-
ﬁers (biological therapy), according to the patient’s need.
Table 1 – Comparisons between patients with early RA divided 
Characteristics ♀ With sexual dysfunction (n = 43) 
Age in years, mean (±SD) 48.51 (±12.59) 
Disease duration (±SD) 6.05 (±2.19) 
DAS-28 (±SD) 3.84 (±1.53) 
HAQ 0.80 
Education
Illiterate (n %) 2 (4.65%) 
<7 years of education (n %) 13 (30.23%) 
>7 years of education (n %) 28 (65.11%) 
Marital status
Married (n %) 24 (55.81%) 
Stable union (n %) 8 (18.60%) 
Single (n %) 3 (6.97%) 
Separate (n %) 6 (13.95%) 
Widower (n %) 2 (4.65%) 
Weight
Normal weight (n %) 17 (40.47%) 
Overweight (n %) 17 (40.47%) 
Obesity (n %) 8 (19.04%) 
a Student’s t-test.
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Currently, patients followed per protocol for up to 10 years after
the initial diagnosis participate in this cohort.
The study was conducted from January to May 2012, with
direct interviews and clinical record reviews. Information on
age, duration of disease, years of education, marital status,
Disease Activity Score 28 (DAS-28)20 and functional disability
questionnaire (Health Assessment Questionnaire – HAQ) were
obtained.21
The presence of sexual dysfunction was assessed through
completion of the Female Sexual Function Index (FSFI), a
questionnaire proposed by Rosen et al. in 200022,23 and vali-
dated for the Portuguese idiom by Pacagnella et al. in 20099
FSFI is a self-administered questionnaire that aims to assess
female sexual response into six domains: sexual desire, sexual
arousal, vaginal lubrication, orgasm, sexual satisfaction and
pain. FSFI presents 19 questions that evaluate sexual func-
tion in the last four weeks. Each question receives a score
ranging from 0 to 5 points, and the end result is the sum of
the scores for each domain, multiplied by a correction fac-
tor that homogenizes the inﬂuence of each domain. A total
score ≤26 indicates sexual dysfunction.9,22,23 Given that the
instrument used in this study to assess sexual function con-
templated only female patients, male patients were excluded
from the analysis.
Female patients selected consecutively into Brasilia Cohort
participated as volunteers in the study, after clariﬁcation
on its content and after signing the Free and Informed
Consent Form. The study was approved by the Ethics Com-
mittee, Medicine School, Universidade de Brasília (CEP-FM
030/2010).Statistical  analysis
A descriptive analysis was used to describe the general char-
acteristics of the population. Student’s t or Mann–Whitney
into groups with and without sexual dysfunction.
♀ Without sexual dysfunction (n = 11) P
42.09 (±12.64) 0.208a
5.0 (±2.28) 0.13a
3.32 (±1.29) 0.29a
0.39 0.09a
1 (9.09%) 0.502b
2 (18.18%) 0.253b
9 (81.81%) 0.470b
8 (72.72%) 0.493b
0 0.184b
2 (18.18%) 0.266b
1 (9.09%) 1.0b
0 1.0b
4 (44.44%) 1.000b
4 (44.44%) 1.000b
1 (11.11%) 0.667b
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Table 2 – FSFI domains discriminated.
FSFI domains Possible answers
Domain: sexual desire
Question # 1 – In the last four weeks, how often did
you feel desire or sexual interest?
1.  Almost always or always
2. Most of the time (more than half of the time)
3. Sometimes (about half of the time)
4. A few times (less than half the time)
5. Almost never, or never
Question # 2 – In the last four weeks, how do you
rate your level of desire or sexual interest?
1  Very high
2. High
3 Moderate
4 Low
5 Very low or absolutely absent
Domain: sexual arousal
Question # 3 – In the last four weeks, how often you
felt sexually aroused during sexual activity or
intercourse?
1.  No sexual activity
2. Almost always, or always
3. Most of the time (more than half of the time)
4. Sometimes (about half of the time)
5. A few times (less than half the time)
6. Almost never, or never
Question # 4 – In the past 4 weeks, how would you
rate your level of sexual arousal during sexual
activity or intercourse?
1.  No sexual activity
2. Very high
3. High
4. Moderate
5. Low
6. Very low, or absolutely absent
Question # 5 – In the last four weeks, how do you
rate your level of assurance to become sexually
aroused during sexual activity or intercourse?
1.  No sexual activity
2. Very high assurance
3. High assurance
4. Moderate assurance
5. Low assurance
6. Very low or no assurance
Question # 6 – In the past 4 weeks, how often you
were satisﬁed with your sexual arousal during
sexual activity or intercourse?
1.  No sexual activity
2. Almost always, or always
3. Most of the time (more than half of the time)
4. Sometimes (about half of the time)
5. A few times (less than half the time)
6. Almost never, or never
Domain: vaginal lubrication
Question # 7 – In the last four weeks, how often you
had vaginal lubrication (got a “wet” vagina) during
sexual activity or intercourse?
1.  No sexual activity
2. Almost always, or always
3. Most of the time (more than half of the time)
4. Sometimes (about half of the time)
5. A few times (less than half the time)
6. Almost never, or never
Question # 8 – In the last four weeks, how do you
rate your difﬁculty in having vaginal lubrication (got
a “wet” vagina) during intercourse or sexual
activities?
1.  No sexual activity
2. Extremely difﬁcult, or impossible
3. Very difﬁcult
4. Difﬁcult
5. Slightly difﬁcult
6. Not at all difﬁcult
Question # 8 – In the last four weeks, how do you
rate your difﬁculty in having vaginal lubrication (got
a “wet” vagina) during intercourse or sexual
activities?
1.  No sexual activity
2. Extremely difﬁcult, or impossible
3. Very difﬁcult
4. Difﬁcult
5. Slightly difﬁcult
6. Not at all difﬁcult
Question # 9 – In the last four weeks, how often you
kept vaginal lubrication (got a “wet” vagina) until
the end of sexual activity or intercourse?
1.  No sexual activity
2. Almost always, or always
3. Most of the time (more than half of the time)
4. Sometimes (about half of the time)
5. A few times (less than half the time)
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Table 2 – (Continued)
FSFI domains Possible answers
6. Almost never, or never
Question # 10 – In the last four weeks, which was
your difﬁculty in maintaining vaginal lubrication
(stay with a “wet” vagina) until the end of the sexual
activity or intercourse?
1.  No sexual activity
2. Extremely difﬁcult, or impossible
3. Very difﬁcult
4. Difﬁcult
5. Slightly difﬁcult
6. Not at all difﬁcult
Domain: orgasm
Question # 11 – In the last four weeks, when you had
sexual stimulation or practiced intercourse, how
often you reached orgasm (“sexual climax”)?
1.  No sexual activity
2. Almost always, or always
3. Most of the time (more than half of the time)
4. Sometimes (about half of the time)
5. A few times (less than half the time)
6. Almost never, or never
Question # 12 – In the last four weeks, when you had
sexual stimulation or practiced intercourse, which
was your difﬁculty in reaching orgasm (sexual
climax)?
1.  No sexual activity
2. Extremely difﬁcult, or impossible
3. Very difﬁcult
4. Difﬁcult
5. Slightly difﬁcult
6. Not at all difﬁcult
Question # 13 – In the past 4 weeks, how satisﬁed
were you with your ability to reach orgasm (sexual
climax) during sexual activity or intercourse?
1.  No sexual activity
2. Very satisﬁed
3. Moderately satisﬁed
4. Almost equally satisﬁed and dissatisﬁed
5. Moderately dissatisﬁed
6. Very dissatisﬁed
Domain: sexual satisfaction
Question # 14 – In the past 4 weeks, how satisﬁed
have you been with the emotional closeness
between you and your partner during sexual
activity?
1.  No sexual activity
2. Very satisﬁed
3. Moderately satisﬁed
4. Almost equally satisﬁed and dissatisﬁed
5. Moderately dissatisﬁed
6. Very dissatisﬁed
Question # 15 – In the past 4 weeks, how satisﬁed
have you been with sexual relationship between you
and your partner?
1.  No sexual activity
2. Very satisﬁed
3. Moderately satisﬁed
4. Almost equally satisﬁed and dissatisﬁed
5. Moderately dissatisﬁed
6. Very dissatisﬁed
Question # 16 – In the past 4 weeks, how satisﬁed
have you been with your sexual life in general?
1.  No sexual activity
2. Very satisﬁed
3. Moderately satisﬁed
4. Almost equally satisﬁed and dissatisﬁed
5. Moderately dissatisﬁed
6. Very dissatisﬁed
Domain: pain
Question # 17 – In the last four weeks, how often you
felt discomfort or pain during vaginal penetration?
1.  No sexual activity
2. Almost always, or always
3. Most of the time (more than half of the time)
4. Sometimes (about half of the time)
5. A few times (less than half the time)
6. Almost never, or never
Question # 18 – In the last four weeks, how often you
feel discomfort or pain following vaginal
penetration?
1.  No sexual activity
2. Almost always, or always
3. Most of the time (more than half of the time)
4. Sometimes (about half of the time)
5. A few times (less than half the time)
6. Almost never, or never
Question 19 – In the past 4 weeks, how would you
rate your level of discomfort or pain during or
following vaginal penetration?
1.  No sexual activity
2. Very high
3. High
4. Moderate
5. Low
6. Very low, or absolutely absent
 o l . 2 0 1 5;5 5(2):123–132
Table 3 – Results detailed for each of the six domains of
FSFI.
FSFI domains ♀ With sexual
dysfunction (n = 43)
♀ Without sexual
dysfunction (n = 11)
Domain: sexual desire
Question # 1 (n %) 1 (2.32%) 3 (27.27%)
1 (2.32%) 3 (27.27%)
5 (11.62%) 3 (27.27%)
21 (48.83%) 2 (18.18%)
15 (34.88%) 0
Question # 2 (n %) 0 0
0 2 (18.18%)
12 (27.90%) 8 (72.72%)
19 (44.18%) 1 (9.09%)
12 (27.90%) 0
Domain: sexual arousal
Question # 3 (n %) 2 (4.65%) 0
2 (4.65%) 5 (45.45%)
2 (4.65%) 1 (9.09%)
6 (13.95%) 5 (45.45%)
16 (37.20%) 0
15 (34.88%) 0
Question # 4 (n %) 1 (2.32%) 0
0 1 (9.09%)
0 5 (45.45%)
12 (27.90%) 5 (45.45%)
15 (34.88%) 0
15 (34.88%) 0
Question # 5 (n %) 10 (23.25%) 0
1 (2.32%) 2 (18.18%)
0 4 (36.36%)
15 (34.88%) 5 (45.45%)
7 (16.27%) 0
10 (23.25%) 0
Question # 6 (n %) 10 (23.25%) 0
2 (4.65%) 8 (72.72%)
4 (9.30%) 2 (18.18%)
8 (18.60%) 1 (9.09%)
11 (25.58%) 0
8 (18.60%) 0
Domain: vaginal lubrication 8 (18.60%) 0
Question # 7 (n %) 4 (9.30%) 6 (54.54%)
4 (9.30%) 1 (9.09%)
5 (11.62%) 4 (36.36%)
14 (32.55%) 0
8 (18.60%) 0
Question # 8 (n %) 10 (23.25%) 0
1 (2.32%) 0
6 (13.95%) 1 (9.09%)
10 (23.25%) 1 (9.09%)
8 (18.60%) 2 (18.18%)
8 (18.60%) 7 (63.63%)
Question # 9 (n %) 9 (20.93%) 0
3 (6.97%) 6 (54.54%)
5 (11.62%) 3 (27.27%)
6 (13.95%) 0
10 (23.25%) 2 (18.18%)
10 (23.25%) 0
Question # 10 (n %) 13 (30.23%) 0
1 (2.32%) 0
4 (9.30%) 0
8 (18.60%) 1 (9.09%)
9 (20.93%) 2 (18.18%)128  r e v b r a s r e u m a t
test was used to analyze continuous variables. Categorical
variables were analyzed by Chi-squared or Fisher’s exact test,
where appropriate. We  considered P < 0.05 as statistically sig-
niﬁcant.
Results
Of the 78 patients with early RA evaluated in the period, 68
female patients (87.1% of the sample) were selected; 10 male
patients (12.8% of the sample) were excluded. The mean age
of the study population was 49.7 ± 13.7 years (mean ± SD).
Regarding marital status, 61.4% (35 patients) reported being
married, 11.7% (8 patients) reported maintaining a stable rela-
tionship with a partner, 13.2% (9 patients) reported being
single, 8 patients (11.7%) declared themselves separate and 8
patients (11.7%) reported being widowed. With regard to edu-
cation, 4.4% of patients were illiterate, 32.3% had between 1
and 7 years of formal education and 63.2% reported more  than
7 years of schooling.
Fifty-four women (79.4%) reported sexual activity in the last
four weeks and 14 (20.5%) declared themselves with no sexual
activity in the month preceding the questionnaire. The preva-
lence of sexual dysfunction (FSFI ≤26) among the 54 patients
with sexual activity was 79.6% (43 patients).
The general characteristics of patient groups with and
without sexual dysfunction are shown in Table 1. In the sexual
dysfunction group (43 patients), 97.67% were using synthetic
DMARDs and 13.95% were using biological DMARDs (inﬂix-
imab, 2; adalimumab, 1; abatacept, 2; and rituximab, 1 patient).
In the group without sexual dysfunction (11 patients),
90.90% were using synthetic DMARDs and 18.18% were using
biological DMARDs (inﬂiximab, 1 patient; and rituximab, 1
patient).
Tables 2 and 3 show, respectively, the domains of FSFI and
the possible outcomes, separately for each one of question-
naire’s questions.
In the evaluation of different age groups, we  observed dif-
ferences in affected domains in FSFI in the groups with and
without sexual dysfunction (Table 4). In the group aged 51–60
years and in that group ≥61 years, only one patient in each
group showed no sexual dysfunction. Regarding the status of
“no sexual activity” in the last four weeks, we observed the
following distribution according to age groups: ≤ 30 years,
20% (n = 1) of patients had no sexual activity; 31–40 years, all
patients had an active sexual life; 41–50, 6.7% had no sexual
activity; 51–60, 24% (n = 4) had no sexual intercourse; ≥61 years,
47% (n = 8) had no sexual activity.
There was no statistical difference between groups (with
and without sexual dysfunction) with respect to marital sta-
tus, length of formal education, body mass index (BMI),
disease activity (DAS-28), functional disability (HAQ) or use
medications (synthetic DMARDs and biologicals).
DiscussionRA can inﬂuence sexual function in several aspects.10 The rea-
sons for disturbance in sexual functioning are multifactorial
and include aspects related to the disease itself, as well as
8 (18.60%) 8 (72.72%)
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Table 3 – (Continued)
FSFI domains ♀ With sexual
dysfunction (n = 43)
♀ Without sexual
dysfunction (n = 11)
Domain: orgasm
Question # 11 (n %) 11 (25.58%) 0
0 5 (45.45%)
2 (4.65%) 4 (36.36%)
5 (11.62%) 1 (9.09%)
16 (37.20%) 1 (9.09%)
9 (20.93%) 0
Question # 12 (n %) 11 (25.58%) 0
1 (2.32%) 0
7 (16.27%) 0
10 (23.25%) 0
9 (20.93%) 3 (27.27%)
5 (11.62%) 8 (72.72%)
Question # 13 (n %) 14 (32.55%) 0
2 (4.65%) 7 (63.63%)
10 (23.25%) 4 (36.36%)
5 (11.62%) 0
6 (13.95%) 0
6 (13.95%) 0
Domain: sexual satisfaction
Question # 14 (n %) 14 (32.55%) 0
5 (11.62%) 9 (81.81%)
9 (20.93%) 1 (9.09%)
6 (13.95%) 0
5 (11.62%) 1 (9.09%)
4 (9.30%) 0
Question # 15 (n %) 15 (34.88%) 0
5 (11.62%) 10 (90.90%)
9 (20.93%) 1 (9.09%)
8 (18.60%) 0
5 (11.62%) 0
1 (2.32%) 0
Question # 16 (n %) 13 (30.23%) 0
1 (2.32%) 8 (72.72%)
11 (25.58%) 3 (27.27%)
5 (11.62%) 0
6 (13.95%) 0
7 (16.27%) 0
Domain: pain
Question # 17 (n %) 11 (25.58%) 0
6 (13.95%) 0
2 (4.65%) 1 (9.09%)
7 (16.27%) 0
8 (18.60%) 0
9 (20.93%) 10 (90.90%)
Question # 18 (n %) 11 (25.58%) 0
4 (9.30%) 0
3 (6.97%) 0
3 (6.97%) 1 (9.09%)
10 (23.25%) 1 (9.09%)
12 (27.90%) 9 (81.81%)
Question # 19 (n %) 12 (27.90%) 0
3 (6.97%) 0
1 (2.32%) 0
11 (25.58%) 1 (9.09%)
4 (9.30%) 1 (9.09%)
12 (27.90%) 9 (81.81%) 5;5 5(2):123–132 129
to treatment.7,24 Physical and emotional problems and dif-
ﬁculties in ﬁnding partnership as a result of disease-related
stress contribute to a less active and often less pleasant sex-
ual life.7,24 Chronic pain, fatigue and low self-esteem can
diminish the sexual interest, thus reducing the frequency of
intercourse.7,24
In our study, we found a high frequency of sexual dys-
function (79.6%) of patients with active sexual life, a higher
ﬁgure than in most previous studies in patients with estab-
lished RA.4,7,10–12 Abdel-Nasser et al.3 showed in their study
that over 60% of female patients with RA had difﬁculty in sex-
ual performance (sexual disability) and a signiﬁcant decrease
in sex drive.3
In a previous study conducted by our group25 that evaluated
163 patients with diagnoses of various rheumatic diseases,
including 24 patients with established RA, we found sex-
ual dysfunction in 18.4% of evaluated patients, and 8.3% of
patients with RA had a FSFI score <26. It is important to men-
tion that in this previous study, 24.2% of all patients and
17% of RA patients had no sexual activity during the study
period. However, we would expect a lower frequency of sex-
ual dysfunction in patients with early RA than in those with
established RA, in view of an earlier treatment, and possibly
the presence of less deformity in patients with early disease.
This difference in prevalence may be explained by other fac-
tors that inﬂuence sexual function, such as emotional issues
and comorbidities, such as depression, which were not eval-
uated in our study. In support of this explanation, Karlsson
et al.26 found that patients with early RA are less satisﬁed
with their life as a whole, compared with a reference group
of patients with long-term illness.
Patients with early RA also reported low levels of satis-
faction with self-care, work and sexual life activities.7,26 In
our study, we  did not evaluate labor and self-care ability vari-
ables.
Hill et al. evaluated the effect of RA on the rela-
tionship between partners and demonstrated that 35% of
patients believed that the disease interfered with the rela-
tionship with the partner, due to problems such as decrease
in daily and social activities and emotional and ﬁnancial
changes.4,6
In the present study, we  found no association between
the occurrence of sexual dysfunction and disease activity.
Also, no signiﬁcant association between functional disability
and sexual dysfunction was observed. However, in the study
of Abdel-Nasser et al.,3 sexual disability was related, among
other factors, to disease activity, pain and disability measured
by HAQ. In another study, El Miedany et al.10 showed a preva-
lence of 45.7% of SD in female patients diagnosed with RA,
showing correlation of SD with several markers of disease
activity.
We  observed the inﬂuence of age in relation to sexual
dysfunction, as expected. With increasing age, more  of FSFI
domains were affected, with an increase of the percentage of
patients without sexual activity.
In 2007, a French study from the Association Franc¸aise
des Polyarthritiques evaluated the impact of RA on patients’
sexuality by sending questionnaires to about 7700 patients.
Of the patients who returned completed questionnaires,
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Table 4 – FSFI domains according to age groups.
Age groups and FSFI domains ♀ With sexual dysfunction
(n = 43)
♀ Without sexual
dysfunction (n = 11)
P
≤30 years
n 2 2 –
Sexual desire 2.7 ± 0.42 3.9 ± 0.42 0.10
Sexual arousal 2.7 ± 0.42 5.5 ± 0.21 0.013
Vaginal lubrication 3.45 ± 0.21 4.95 ± 1.48 0.29
Orgasm 3.2 ± 0.56 6 ± 0 0.019
Sexual satisfaction 2.6 ± 0.84 5.8 ± 0.28 0.003
Pain 3.8 ± 0.84 4.6 ± 1.9 0.65
31–40 years
n 11 3 –
Sexual desire 2.56 ± 0.54 4.4 ± 0.91 0.0006
Sexual arousal 2.80 ± 0.98 4.9 ± 0.62 0.005
Vaginal lubrication 3.7 ± 1.67 5.6 ± 0.45 0.08
Orgasm 3.09 ± 1.37 5.3 ± 0.61 0.019
Sexual satisfaction 3.63 ± 1.5 5.6 ± 0.69 0.05
Pain 4.1 ± 1.66 6 ± 0 0.85
41–50 years
n 10 4 –
Sexual desire 2.34 ± 1.07 4.05 ± 0.9 0.01
Sexual arousal 2.22 ± 1.29 4.57 ± 0.99 0.007
Vaginal lubrication 2.9 ± 2.09 5.1 ± 1.06 0.07
Orgasm 2.76 ± 1.8 5.3 ± 0.94 0.02
Sexual satisfaction 3 ± 1.84  6 ± 0 0.008
Pain 3.08 ± 2.22 5.9 ± 0.2 0.02
Student’s t-test used in all these analyzes.51% reported an adverse impact of the disease on their
sexuality.10,11,27
Studies in RA patients unselected for disease duration sug-
gest that obesity is associated independently with a worse
quality of life.28 Obesity is associated with higher concen-
trations of inﬂammation markers such as C-reactive protein
(CRP), interleukin 6 (IL-6) and tumor necrosis factor alpha
(TNF-) and therefore obese RA patients may present with a
more  severe and active disease.28,29
García-Poma et al.29 reported that, in patients with RA, the
health-related quality of life is impaired due to several factors.
In their study, these authors suggest that patients with RA
who  are obese are more  likely to present a reduced quality
of life compared with normal-weight patients, regardless of
other characteristics such as gender, age, activity of disease,
extra-articular disease, presence of rheumatoid factor, level of
depression, socioeconomic status, or disease duration. In this
study, we  found no direct relationship between the prevalence
of sexual dysfunction and the occurrence of obesity among
patients with early RA.
Sexual functioning is a neglected area of quality of life
in patients with rheumatic diseases.7 Rheumatologists are
increasingly willing to discuss areas that are not directly
related to the pharmacological treatment of joint diseases,
such as quality of life, fatigue and patient education. How-
ever, sexuality is rarely addressed in relation to the quality of
life.11,30
In a recent survey with ten rheumatologists, only 12% of
patients seen in their clinical practice have been evaluated forsexual activity.31 This apparent lack of interest, by the physi-
cian, with respect of the sexual function of their patients could
be explained, according to respondents, by factors such as
limited consultation time, discomfort when discussing sexu-
ality (both by physician and patient), and uncertainties about
the role of the doctors and their competence on issues of
patients’ sexuality.3,7,11,31 This demonstrates the importance
of further studies that evaluate sexual function in rheumatic
diseases and their disclosure among experts, aiming at a more
comprehensive treatment of patients.
Our study has some limitations. This is a cross-sectional
study, which, thus, does not allow the establishment of a
cause-effect relationship. The number of female patients
evaluated in this study was relatively small, especially the
number of patients with early RA without sexual dysfunc-
tion, which constituted a minority of the total number of
assessed women. Another limiting factor was the fact that
the patients were evaluated in a cohort study in a ter-
tiary hospital, a regional reference in Rheumatology. Thus,
probably our evaluated female patients had more  severe con-
ditions than patients followed up in a primary health care
service. Furthermore, we did not evaluate other comorbidi-
ties that may inﬂuence sexual function, such as depression
and Sjögren’s syndrome. These factors should be taken into
consideration, so that the results observed should not be
extrapolated for all female patients diagnosed with early
RA.
However, this is the ﬁrst study which we  are aware that
speciﬁcally assesses sexual function in patients with early
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onclusion
he prevalence of sexual dysfunction found in this study was
igher compared both with the ﬁgures published in the lit-
rature in healthy women (up to 40%), as those found in
atients with rheumatoid arthritis (31–76%), including previ-
us cases of established RA in our Service. Given that sexuality
s regarded as one of the major determinants of reduced qual-
ty of life, questions that address these aspects should be
mong the parameters that evaluate the course of disease.
tudies assessing the extent of sexual dysfunction in a speciﬁc
anner with respect to patients with early RA are necessary,
o that therapeutic alternatives aiming to improve not only
he physical health, but also the quality of life of the patient,
e offered.
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